| 1 |
34047951 | Effect of Wnt5a on drug resistance in estrogen receptor-positive breast cancer. | 2021 Sep |
1 |
| 2 |
32269999 | A Qualitative Transcriptional Signature for Predicting Extreme Resistance of ER-Negative Breast Cancer to Paclitaxel, Doxorubicin, and Cyclophosphamide Neoadjuvant Chemotherapy. | 2020 |
3 |
| 3 |
30421506 | Potentiation of paclitaxel effect by resveratrol in human breast cancer cells by counteracting the 17β-estradiol/estrogen receptor α/neuroglobin pathway. | 2019 Apr |
2 |
| 4 |
30707920 | Combined bazedoxifene and paclitaxel treatments inhibit cell viability, cell migration, colony formation, and tumor growth and induce apoptosis in breast cancer. | 2019 Apr 28 |
1 |
| 5 |
31149728 | Cytochrome c1 as a favorable prognostic marker in estrogen receptor-positive breast carcinoma. | 2019 Dec |
2 |
| 6 |
29373839 | Nogo-B receptor increases the resistance of estrogen receptor positive breast cancer to paclitaxel. | 2018 Apr 10 |
3 |
| 7 |
30179299 | Isobavachalcone sensitizes cells to E2-induced paclitaxel resistance by down-regulating CD44 expression in ER+ breast cancer cells. | 2018 Nov |
3 |
| 8 |
27854072 | SH003 enhances paclitaxel chemosensitivity in MCF-7/PAX breast cancer cells through inhibition of MDR1 activity. | 2017 Feb |
1 |
| 9 |
29254147 | Measurement of molecular biomarkers that predict the tumor response in estrogen receptor-positive breast cancers after dose-dense (biweekly) paclitaxel/carboplatin neoadjuvant chemotherapy. | 2017 Nov 24 |
4 |
| 10 |
26964739 | Dynamic modulation of phosphoprotein expression in ovarian cancer xenograft models. | 2016 Mar 10 |
1 |
| 11 |
26980709 | ERα propelled aberrant global DNA hypermethylation by activating the DNMT1 gene to enhance anticancer drug resistance in human breast cancer cells. | 2016 Apr 12 |
3 |
| 12 |
27312786 | Neuroglobin overexpression induced by the 17β-Estradiol-Estrogen receptor-α Pathway reduces the sensitivity of MCF-7 Breast cancer cell to paclitaxel. | 2016 Aug |
4 |
| 13 |
27845892 | LncRNA H19 confers chemoresistance in ERα-positive breast cancer through epigenetic silencing of the pro-apoptotic gene BIK. | 2016 Dec 6 |
2 |
| 14 |
26232188 | The presence of Estrogen Receptor β modulates the response of breast cancer cells to therapeutic agents. | 2015 Sep |
2 |
| 15 |
26714597 | [Effect of estrogen or progesterone combined with paclitaxel on human ovarian cancer cell growth and Drosha expression]. | 2015 Aug |
1 |
| 16 |
24786296 | ERα directly activated the MDR1 transcription to increase paclitaxel-resistance of ERα-positive breast cancer cells in vitro and in vivo. | 2014 Aug |
3 |
| 17 |
25453096 | Hypoxia-inducible factors are required for chemotherapy resistance of breast cancer stem cells. | 2014 Dec 16 |
1 |
| 18 |
25534230 | Anti-tumor efficacy of fulvestrant in estrogen receptor positive gastric cancer. | 2014 Dec 23 |
1 |
| 19 |
24114859 | Association of somatic DNA methylation variability with progression-free survival and toxicity in ovarian cancer patients. | 2013 Nov |
1 |
| 20 |
24376711 | Induction of paclitaxel resistance by ERα mediated prohibitin mitochondrial-nuclear shuttling. | 2013 |
4 |
| 21 |
21909982 | Estrogen receptor-α directly regulates sensitivity to paclitaxel in neoadjuvant chemotherapy for breast cancer. | 2012 Jun |
7 |
| 22 |
22018777 | 70-Gene classifier for differentiation between paclitaxel- and docetaxel-sensitive breast cancers. | 2012 Jan 28 |
1 |
| 23 |
22433870 | Tyrosine-phosphorylated caveolin-1 (Tyr-14) increases sensitivity to paclitaxel by inhibiting BCL2 and BCLxL proteins via c-Jun N-terminal kinase (JNK). | 2012 May 18 |
1 |
| 24 |
22578285 | A target based approach identifies genomic predictors of breast cancer patient response to chemotherapy. | 2012 May 11 |
1 |
| 25 |
23023313 | Taxol-induced growth arrest and apoptosis is associated with the upregulation of the Cdk inhibitor, p21WAF1/CIP1, in human breast cancer cells. | 2012 Dec |
2 |
| 26 |
21801281 | Combination treatment with fulvestrant and various cytotoxic agents (doxorubicin, paclitaxel, docetaxel, vinorelbine, and 5-fluorouracil) has a synergistic effect in estrogen receptor-positive breast cancer. | 2011 Nov |
1 |
| 27 |
19455332 | Preclinical rationale for combined use of endocrine therapy and 5-fluorouracil but neither doxorubicin nor paclitaxel in the treatment of endocrine-responsive breast cancer. | 2010 Jan |
5 |
| 28 |
21224536 | [The combined effect of Paclitaxel and toremifene therapy for estrogen receptor positive and aromatase inhibitor resistant metastatic breast cancer]. | 2010 Nov |
1 |
| 29 |
19148464 | Resistance to paclitaxel therapy is related with Bcl-2 expression through an estrogen receptor mediated pathway in breast cancer. | 2009 Feb |
2 |
| 30 |
19340624 | The vitamin A family can significantly decrease the expression of ERbeta of ERs positive breast cancer cells in the presence or absence of ER ligands and paclitaxel. | 2009 May |
2 |
| 31 |
19364972 | Genomic grade index is associated with response to chemotherapy in patients with breast cancer. | 2009 Jul 1 |
3 |
| 32 |
19949674 | Impact of grade, hormone receptor, and HER-2 status in women with breast cancer on response to specific chemotherapeutic agents by in vitro adenosine triphosphate-based chemotherapy response assay. | 2009 Dec |
1 |
| 33 |
18937711 | Expression of melatonin receptor (MT1) and interaction between melatonin and estrogen in endometrial cancer cell line. | 2008 Aug |
1 |
| 34 |
17293601 | Inclusion of taxanes, particularly weekly paclitaxel, in preoperative chemotherapy improves pathologic complete response rate in estrogen receptor-positive breast cancers. | 2007 May |
1 |
| 35 |
17545614 | Estrogen receptor alpha mediates breast cancer cell resistance to paclitaxel through inhibition of apoptotic cell death. | 2007 Jun 1 |
6 |
| 36 |
18083698 | Markers predicting clinical benefit in breast cancer from microtubule-targeting agents. | 2007 Dec |
1 |
| 37 |
16609087 | Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. | 2006 Apr 12 |
1 |
| 38 |
14987051 | Design, synthesis, and bioactivities of steroid-linked taxol analogues as potential targeted drugs for prostate and breast cancer. | 2004 Feb |
2 |
| 39 |
15012603 | Regulation of estrogen receptor-alpha expression in MCF-7 cells by taxol. | 2004 Mar |
7 |
| 40 |
15020841 | Estrogen receptor expression and sensitivity to paclitaxel in breast cancer. | 2004 May |
13 |
| 41 |
15023242 | Paclitaxel improves the prognosis in estrogen receptor negative inflammatory breast cancer: the M. D. Anderson Cancer Center experience. | 2004 Feb |
2 |
| 42 |
15114714 | [Weekly paclitaxel therapy for locoregional lymph node recurrence of estrogen-receptor-negative breast cancer]. | 2004 Apr |
1 |
| 43 |
15685822 | Adjuvant chemotherapy for early-stage breast cancer: the tAnGo trial. | 2004 Dec |
2 |
| 44 |
10976921 | Plasma membrane estrogen receptors signal to antiapoptosis in breast cancer. | 2000 Sep |
2 |
| 45 |
10630357 | Synergistic effect of paclitaxel and 4-hydroxytamoxifen on estrogen receptor-negative colon cancer and lung cancer cell lines. | 1999 Nov |
5 |